• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush

    Post-Pandemic Partnerships: A Full-Service Outsourcing Discussion

    Discovering the Value of Surface Treatments and Coatings for Medtech
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    Linear Health Sciences’ Orchid SRV Receives FDA & Health Canada Approval

    Vivasure Medical Raises $23 Million in Series D Financing Round

    New Patents Add Value to Know Labs' Bio-RFID Tech

    Ra Medical Granted Patent for Catheters With Expanded Ablation Area

    ReCor Medical Presents Data from Two Randomized Trials
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Cybersecurity Challenges Leave Medical Device Makers Insecure

    OEMs Are Demanding Designs that Challenge Suppliers

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush

    Post-Pandemic Partnerships: A Full-Service Outsourcing Discussion

    Discovering the Value of Surface Treatments and Coatings for Medtech
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Injecting Neurostimulators into Blood Vessels (We Swear, It’s Not Sci-Fi)

    Understanding the Costs of Care in the OR

    Sick of Being Sick: Pandemic Fatigue Flares at AAOS

    Managing Critical Healthcare Supply Chains in Turbulent Times

    To Drive Value, Human Capital Leaders Turn to Outsourced Solutions
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Arthur G. Russell Co. Inc., The

    Fusion Biotec Inc.

    Trademark Plastics Inc.

    Cirtec Medical

    Concise Engineering
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    3D Printing in Dental Prosthodontics, Orthodontics, and Surgery

    What New Tech Can Improve Your Medical Manufacturing Plant?

    Why Medical Device Firms Must Navigate the Muddy Waters of ESG Requirements

    Medical Device Servicing vs. Remanufacturing

    Digital Marketplaces for Medical Equipment Come of Age
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Arthur G. Russell Co. Inc., The

    Fusion Biotec Inc.

    Trademark Plastics Inc.

    Cirtec Medical

    Concise Engineering
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Features

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush

    Examining recent diabetes technology innovations and market trends as well as manufacturing partners to the industry.

    Diabetes Technology Manufacturers Seemingly on a Sugar Rush
    The Garmin and Dexcom product family. Image courtesy of Dexcom.
    Diabetes Technology Manufacturers Seemingly on a Sugar Rush
    The Omnipod 5 insulin delivery device integrates with the Dexcom G6 CGM. Image courtesy of Insulet.
    Diabetes Technology Manufacturers Seemingly on a Sugar Rush
    The Dexcom G7 CGM, which is currently under FDA review. Image courtesy of Dexcom.
    Diabetes Technology Manufacturers Seemingly on a Sugar Rush
    An overmolded needle for diabetes applications. Image courtesy of Isometric Micro Molding.
    Diabetes Technology Manufacturers Seemingly on a Sugar Rush
    The Eversense E3 implantable CGM was launched in the U.S. in April. Image courtesy of Senseonics.
    Sam Brusco, Associate Editor05.02.22
    It’s been a productive last few years for diabetes management technology.

    Diabetes patients previously had to get used to pricking their fingers several times a day to track their blood glucose levels. But the continuous glucose monitor (CGM) has offered patients enormous relief. A CGM still requires the sensor to be inserted with a brief needle poke when it’s placed, but today’s sensors can be worn for weeks or even months. Plus, they’re so small patients may often forget they have them on the body.

    Insulin pumps were also pretty complicated in the past, often cumbersome and impeding daily activities. But now the devices have become small enough to work with patients’ daily lives, with some delivering continuous and customized doses of rapid-acting insulin 24 hours a day to keep up with the body’s needs. Modern pumps can provide insulin in two ways: basal insulin, small amounts released continuously throughout the day, and bolus insulin, which can be delivered on demand to match food intake or resolve high blood sugar. The pump delivers insulin through a thin flexible tube called an infusion set.

    “Diabetes technology is all about making patients’ lives as tolerable as possible while simultaneously improving outcomes,” Dr. Francine Kaufman, chief medical officer of Senseonics, a Germantown, Md.-based long-term implantable CGM maker, told MPO. “This means patients and healthcare providers are looking for tools to help patients manage their condition more effectively while they live their lives however they choose. People want the choice, functionality, and interoperability that allows them to seamlessly integrate technology to meet their condition’s unique needs.”

    Unfortunately as high-tech diabetes tech innovations improve management of the chronic disease, patients in underserved communities may often lag behind in making the most of insulin pumps and CGMs. Disparities in race, education, income, and location can prevent some patients with diabetes from receiving necessary care. The medical community has made many attempts to make these essential tools available for everyone, and lawmakers have made some headway to prioritize equitable advancements in research, detection, and care.

    “We strive to make Pod therapy universally and globally accessible to everyone requiring daily insulin,” Chuck Alpuche, EVP and COO of Insulet, an Acton, Mass.-based insulin delivery device maker, told MPO. “We work with policymakers and health insurance plans to expand coverage and also secure coverage through the pharmacy channel to offer Omnipod with no up-front cost and no commitment. Our 30-day trial program allows users to experience Omnipod without commitment and we provide financial assistance for those who can’t afford Omnipod (U.S. only).”

    Further, using digital technologies can enable safe, effective remote care for diabetes patients. Digital technologies can’t replace standard care of course, but they can enhance existing care pathways by allowing some virtual appointments or providing near-real time monitoring of the patient’s condition. Remote patient monitoring was a crucial part of care delivery during the COVID-19 pandemic and continues to be, but it’s use doesn’t start and end there. It has the potential to boost or fundamentally change healthcare pathways, improve efficiency, and help deliver better outcomes.

    “We aim to meet people where they are by making real-time adjustments for the world we live in,” Ali Dianaty, VP of product innovation and operations for global medical device maker Medtronic, told MPO. “For many years, we’ve had our CareLink software to connect data between a patient’s pump and their healthcare team. The COVID-19 pandemic illustrated how important this remote connection could be—when people couldn’t visit their doctor and needed a virtual appointment, our software could share important diabetes data and retain continuity of care.”

    San Diego-based continuous glucose monitor (CGM) manufacturer Dexcom’s G6 iCGM (integrated continuous glucose monitoring) system was first authorized through de novo marketing clearance for diabetes patients aged 2 and older in 2018. It was then the first type of CGM authorized by the FDA to be used as part of an integrated system with other medical devices and compatible interfaces—automated insulin dosing systems, insulin pumps, blood glucose meters, or other partner technologies for diabetes management. The G6 Pro, which gathers real-time glucose data over 10 days and offers both blinded and unblinded modes, obtained an FDA nod in 2019.

    Further, G6 received FDA breakthrough status in March for use in the hospital setting, providing a more streamlined and efficient review pathway.

    “Dexcom G6 is the most connected CGM on the market, integrating with insulin pens, pumps (automated insulin delivery systems), and digital health apps like Sugarmate, Glooko, and Garmin,” Dexcom CEO Kevin Sayer told MPO.

    G6 paired with Sugarmate gives CGM users a phone call when glucose levels are below normal while asleep, texts friends or family if the value drops too low, and pings customizable alerts when levels climb, fall, or remain steady but high. With Glooko, G6 users can be remotely monitored, have access to data insights and population management features, and upload data. Via the Dexcom Connect IQ apps (developed by Garmin) patients can quickly view glucose levels and trends on a compatible Garmin smartwatch or cycling computer, even while exercising.

    “We actively look for opportunities to partner with companies that manufacture pumps, pens, and other digital health apps and services to enhance our product and overall user experience,” said Sayer. “The latest examples include Dexcom G6’s integration with hybrid closed-loop systems like Tandem Control-IQ and the Omnipod 5 System, the latter of which received FDA clearance earlier this year.”

    An FDA submission for Dexcom’s latest iteration, G7, was made in Q4 of last year. G7 accuracy and safety data for both type 1 and 2 diabetes was published in Diabetes Technology & Therapeutics this year, demonstrating mean absolute relative difference (MARD) of 8.2 percent for adults using arm-placed sensors and showed excellent accuracy independent of diabetes type or treatment regimen.

    G7 earned a CE mark in March for European diabetes patients aged 2 and older, including pregnant women.

    “Our next-generation Dexcom G7 device takes everything users love about Dexcom G6 and makes it better,” said Sayer. “The wearable will be 60 percent smaller in size, include an intuitive, all-in-one app experience, enhanced alerts, and an easy-to-use optional receiver—people with diabetes and HCPs all highly anticipate these features.”

    This past January, Insulet earned FDA clearance for the latest generation of Omnipod, the Omnipod 5 automated insulin delivery (AID) system. The waterproof, tubeless insulin Pod can be worn almost anywhere the user would inject insulin. Cleared for type 1 diabetes patients aged 6 years and above, Omnipod 5 can be controlled with a compatible smartphone. It also integrates with Dexcom’s G6 CGM to help protect against blood glucose highs and lows.

    Each Pod AID system allows users to trade multiple daily insulin injections for up to 72 hours of continuous insulin—combined with new automated and CGM integrated features.

    “Everything about the Omnipod 5 was designed to be as streamlined and simple as possible to reduce effort, stress, and cognitive burden,” said Alpuche. “In automated mode, it automatically adjusts insulin delivery to protect against highs and lows, day and night. The sophisticated, tubeless, wearable Pod is enhanced with SmartAdjust technology to continuously adjust insulin using a customizable glucose target. It can be fully controlled by a compatible smartphone with no multiple daily injections or tubes, and zero fingersticks.”

    Shortly after Omnipod 5’s clearance, Insulet completed an FDA submission to expand its indication to age 2 and up and anticipates being granted the expanded indication later this year. The company also recently finished a type 2 feasibility study that was shared at this April’s Advanced Technologies & Treatments for Diabetes (ATTD) conference. Insulet will take the results from this study to design its pivotal study in order to expand Omnipod 5 to the type 2 diabetes community.

    “In the wake of Omnipod 5’s launch, we continue to strategically invest in a robust product pipeline,” said Alpuche. “You’ll see us advance this platform in the coming years—our iOS app development is making terrific progress, as is our integration work with Dexcom’s G7 and Abbott’s FreeStyle Libre.”

    The latest iteration of Germantown, Md.-based long-term implantable continuous glucose monitor (CGM) maker Senseonics’ Eversense CGM, the E3, achieved FDA approval in February. The first patient implantation and subsequent launch took place in early April. The E3 features a fully implantable fluorescence-based sensor and removable smart transmitter that provides on-body discreet vibration alerts and transmits glucose level data to a mobile app.

    Eversense E3 requires fewer calibrations compared to previous systems, though fingerstick blood glucose measurements are still needed to calibrate it, when symptoms don’t match CGM info, or when taking tetracycline medications.

    “The key difference about the next-generation Eversense E3 system is its sensor includes a sacrificial boronic acid (SBA) design modification to enhance sensor survival for up to six months—essentially doubling its lifetime,” said Dr. Kaufman. “This will make it the longest lasting CGM system available, with essentially only two sensor replacements required each year. People with diabetes will be able to break free from some aspects of traditional CGM use like regular sensor changes and ongoing ordering of supplies.”

    Senseonics reported results from its PROMISE study last year, which demonstrated excellent accuracy of the new system at six months. The company’s Eversense NOW remote monitoring app also achieved CE mark approval on Android operating systems so users can share data with chosen friends and family members. The company aims to launch the app in Europe soon.

    Medtronic’s latest insulin pump innovation in Europe was the advanced hybrid closed-loop system, which automatically adjusts insulin delivery based on readings from the integrated CGM and automates basal and bolus insulin every five minutes. It leverages the company’s MiniMed 780G system and Guardian Sensor 3.

    “One of the hardest elements for many people living with diabetes is carb counting at meals. We focused on relieving burden around this in the new system,” said Dianaty. “If a person miscalculates carbs, that’s OK—the pump system will spot the problem and automatically adjust to provide the appropriate amount of insulin.”

    Last October Medtronic released one-year, real-world clinical data for 3,211 type 1 diabetes patients aged 15 and below using the MiniMed 780G system with the Guardian Sensor 3 CGM; data showed the advanced hybrid closed-loop algorithm offered stronger glycemic control and protection against lows while sleeping (average time in range 77 percent; overnight time in range 82 percent).

    According to the company, the next-gen MiniMed 780G system with Guardian 4 Sensor is under active FDA review.

    “In the future, we aim to further personalize the automation of diabetes systems. We are working to leverage the power of artificial intelligence to do a lot of the manual work for people using this technology,” said Dianaty. “For example, gesture technology could help identify when food is being consumed by the hand motion a smartwatch can detect. That could be linked to diabetes tech to reduce the number of engagements or touchpoints needed to optimize therapy.

    This can be coupled with predictive analytic capabilities around mealtimes to help identify what’s being consumed with greater accuracy. People react to food in different ways, so these AI advancements with personalization could change the ease of managing diabetes.”

    Advanced diabetes technology was further expanded in December when the U.S. Centers for Medicare & Medicaid Services (CMS) issued a ruling to expand Medicare coverage for all CGMs, both adjunctive and non-adjunctive. This included CGMs that integrate with Medtronic’s insulin pumps. The ruling became effective in mid-February.

    CGMs and insulin pumps contain a number of specialized components to accomplish their lifesaving work. Most CGMs contain a monitor to display the information—in some cases, the patient’s mobile device—a sensor usually inserted into the subcutaneous tissue, and a transmitter that sends sensor data to the monitor.

    An insulin pump is also typically made up of four main parts. One is a small cartridge of insulin called a reservoir. A thin plastic tube called a cannula sits under the skin. Flexible plastic tubing connects the cannula to the reservoir. And a pump allows patients to set and change the amount of insulin delivered.

    Some of these components are quite small, especially with diabetes management devices’ need to be discreet and not impede the wearer’s daily life. Making these components requires the ability to manufacture parts with form factors and tolerances that traditional fabrication methods will not be able to accomplish. For example, some components going into CGMs or insulin pumps require the services of a micromolder who can create these tiny parts.

    “Micromolded components used in diabetes and glucose monitoring are cannulas, sheaths, capillary action fluidic components, pumps, gears, flow restrictors, flow enablers, and miniature valves, to name a few,” said Donna Bibber, CEO of Isometric Micro Molding, a New Richmond, Wis.-based medical-focused micro molder.

    Components like sheaths and cannulas going into diabetes management devices can stretch the limits of manufacturing possibility. These sheaths and cannulas can require extremely thin wall configurations. Some micromolders are able to accomplish this very specialized and precise type of manufacturing. According to Isometric Micro Molding, resin companies have said there’s a limit to the flow length (thickness), but the company has been able to surpass flow lengths and limits.

    “Designing products with multiple part assemblies requires the partnership with a micromolder and preferably one that is also an automated assembler,” said Bibber. “With 16 cavities of one part, 32 cavities of another, and eight cavities of yet another, all the full factorial combinations of each mold parts’ cavities assembled error must equate to at least 1.33 Cpk or better.  The assembly is only as good as the weakest Cpk capable component. Isometric Micro Molding works in tight tolerances including single microns all day, every day and has the mindset and over 30 years of experience to solve problems arising from these challenges. The part may not be micro in size, but the diabetes device’s precision may also require a micromolder’s and automated micro assembler’s skills.”

    The technological innovations around CGMs and insulin pumps have challenged manufacturing partners involved in all facets of the devices’ manufacture.

    “We’re asking polymers to accomplish things they haven’t before,” said Bill Torris, director of medical solutions’ Technical Design Center in North America for Nolato, a developer and producer of polymer-based products. “In previous devices, a needle was glued in place to a piece of plastic, now there’s a wire going under the skin and into the device. This device has power and an antenna so there can’t be liquids present and it has to be sealed. To do that, you have to transmit electricity—plastics are terrible for that because they’re an insulator. So we design and compound silicones and use other polymers that can both conceal and transmit electricity. Part of making a device smaller means getting its components inside to do multiple things.”

    “For example, what may have been a standard rubber O-ring was only sealing,” he continued. “Two or three O-rings may be needed to properly seal the device. You have to consider attachment methods and whether sealing is its only function. You have to also be aware of how much real estate the component takes up.”

    A shrinking form factor for CGMs and insulin pumps means the electronics are smaller and more tightly packed together, yet another challenge for manufacturing partners for these devices.

    “When molding silicone around a battery for a diabetes device, for example, it needs to be sealed but also conduct the electricity to power the device,” said Torris. “We have to explore what kind of methods to manufacture the polymer and also worry about getting the electrical signal out. This could involve laser ablation, plating a rigid plastic, and putting additives in the polymer to conduct electricity.”

    “We have the ability to formulate our own silicones—we’re one of a handful of companies that provides these proprietary materials that need to be used in many diabetes management products,” Torris went on. We can intentionally put additives in to ensure they do or don’t conduct electricity, offset those materials, and start to accomplish what’s necessary. That can either be adding thermal shielding properties or making it more thermally conductive—you’re trying to take heat away from one part of the device and put it into a different part. We do EMC shielding as well because there are more and more electronics in these devices.”

    As diabetes management technologies continue to evolve, manufacturing partners will be further challenged to innovate their own processes alongside the device makers.

    “The capability of molders for tooling is being challenged, and that’s where manufacturing simulation comes in,” said Torris. “Using this you can design a chassis with the fluid path, and can custom create a polymer that’s going to seal and/or conduct to thermally shield or wick away. The need for smaller wearables is driving some components toward micromolding because the process is beneficial for insulin delivery components and much more in the medical field.” 
    Related Searches
    • Chronic Disease
    Related Knowledge Center
    • Chronic Disease

    Related Content


      Breaking News
      • Linear Health Sciences’ Orchid SRV Receives FDA & Health Canada Approval
      • Vivasure Medical Raises $23 Million in Series D Financing Round
      • New Patents Add Value to Know Labs' Bio-RFID Tech
      • Ra Medical Granted Patent for Catheters With Expanded Ablation Area
      • ReCor Medical Presents Data from Two Randomized Trials
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Cybersecurity Challenges Leave Medical Device Makers Insecure
      • Contract Design for Medtech
      • Diabetes Medical Device Technology Update
      • Medtech Full-Service Outsourcing Q&A 2022

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Nootropics and Adaptogens Respond to Demand for Mind and Mood Support
      Sabinsa Honors 70th Anniversary of Diplomacy Between India and Japan
      Solvay Invests in Suanfarma’s Vanillin Production
      Coatings World

      Latest Breaking News From Coatings World

      DIC’s Indian Subsidiary Begins Construction of Coating Resins Production Facility
      Celanese Declares Force Majeure on Acetyl Chain and Acetate Tow Products
      CPI Announces New Hybrid Professional Development Program for 2022
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Linear Health Sciences’ Orchid SRV Receives FDA & Health Canada Approval
      Vivasure Medical Raises $23 Million in Series D Financing Round
      New Patents Add Value to Know Labs' Bio-RFID Tech
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Evotec SE and Sernova Corp Announce Partnership in the Field of Diabetes
      Emergex COVID-19 Vaccine Candidate Successfully Coated onto Zosano Micro-Needle Patch
      Thabor Therapeutics Appoints Jérémie Mariau as CEO
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Aveda is Leaping Bunny Approved by Cruelty Free International
      Smashbox Expands Becca Highlighter Collection
      Bite Beauty Is Closing Later This Year
      Happi

      Latest Breaking News From Happi

      Filipino Cosmetics Company Sunnies Face Enters US Market
      Selig Group Names Adam Sheridan Next President
      Nautica Introduces Oceans Pacific Coast Vegan & Sustainable Fine Fragrance Collection
      Ink World

      Latest Breaking News From Ink World

      Nazdar Ink Technologies to Manufacture VFP Ink Technologies Electronic Inks for US
      Sun Chemical Heads to Flexo and Labels 2022
      PETRONAS Chemicals Group to Acquire Perstorp Group
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Essentra Packaging invests in Landa Nanographic press
      Nazdar to manufacture VFP electronic ink for US Market
      SunDance moves into flexible packaging with HP Indigo
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      H&V Appoints Vice President and General Counsel
      The Honest Company to Sell Diapers, Wipes at Walmart
      Jim Cree Joins Monadnock Nonwovens
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Paragon 28 Launches Grappler Suture Anchor System
      Paul Stellato Appointed Chief Accounting Officer at Zimmer Biomet
      DuPuy Synthes’ INHANCE Shoulder System Cleared by FDA for Reverse Total Shoulder Arthroplasty
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Jabil Strengthens Additive Manufacturing Offerings
      Avery Dennison, Wiliot Partner to Build and Scale the Future of IoT
      HP Delivers Enhanced Platform Capabilities to Accelerate Additive Manufacturing Production at Scale

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login